

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Transcenta Holding Limited

創勝集團醫藥有限公司

(registered by way of continuation in the Cayman Islands with limited liability)

(Stock Code: 6628)

CLARIFICATION ANNOUNCEMENT REGARDING THE GRANT OF AWARD SHARES

Reference is made to the announcement of Transcenta Holding Limited (the “**Company**”) dated December 27, 2023 (the “**Announcement**”). Unless otherwise stated, capitalized terms used herein shall bear the same meanings as defined in the Announcement.

The Company would like to clarify that 713,000 of the Un-granted Shares, instead of 455,000 of the Un-granted Shares, will be used to satisfy certain December Award Grant and the remaining portion of the December Award Grant will be satisfied by new Shares to be issued and allotted pursuant to the Scheme Mandate Limit.

Save as disclosed in this announcement, all information set out in the Announcement remains unchanged.

By Order of the Board
Transcenta Holding Limited
Xueming Qian
*Executive Director and
Chief Executive Officer*

Hong Kong, January 4, 2024

As at the date of this announcement, the board of directors of the Company comprises Dr. Xueming Qian as executive Director and chief executive officer, Mr. Xiaolu Weng as executive Director, Dr. Yining Zhao as chairman and non-executive Director, and Mr. Jiasong Tang, Mr. Zhihua Zhang, Dr. Kumar Srinivasan and Ms. Helen Wei Chen as independent non-executive Directors.